OBJECTIVES:: The first summary of the European Association of Urology (EAU) guidelines
on prostate cancer was published in 2001. These guidelines have been continuously …

This article reviews the issues and controversies relevant to the treatment of advanced
prostate cancer with androgen deprivation therapy. Initially, diethylstilbestrol was used for …

The European Association of Urology (EAU) Guidelines Group for Prostate Cancer have
prepared this guidelines document to assist medical professionals assess the evidence …

Purpose Antiandrogen withdrawal (AAWD) results in a prostate-specific antigen (PSA)
response (decline in PSA level of≥ 50%) in 15% to 30% of androgen-independent prostate …

Androgen deprivation is still the standard systemic therapy for metastatic prostate cancer
(PCa), but patients invariably relapse with a more aggressive form of PCa termed hormone …

PURPOSE To discuss the evolution of new concepts in the Use of second-line hormonal
therapy for patients with progressive prostate cancer despite androgen deprivation. DESIGN …

PURPOSE: Androgen ablation remains the cornerstone of management for advanced
prostate cancer. Therapeutic options in patients with progressive disease following …

The molecular mechanisms underlying lethal castration-resistant prostate cancer remain
poorly understood, with intratumoral heterogeneity a likely contributing factor. To examine …

Prostate cancer is the most common cancer diagnosed in American males, and is the
second leading cause of cancer-related deaths. Most patients who develop metastatic …

ABSTRACT Introduction: Prostate cancer (PCa) is currently the second most common
cancer affecting men worldwide. Metastatic castration-resistant prostate cancer (mCRPC) is …